Unidade Local De Saude Da Regiao De Aveiro E.P.E. — Clinical Trial Site

39 Registered trials

14 Currently recruiting

Organisation

Unidade Local De Saude Da Regiao De Aveiro E.P.E.

Location

Aveiro, Portugal

Identifier

ORG-100044351

Address

Avenida De Artur Ravara, 3814-501, Portugal

Departments

#7100:Dermatologia
Cardiology
Centro Hospitalar de Baixo Vouga
Centro Hospitalar de Baixo Vouga( #1)
Hematology
Immunoallergology
Infectiology
Internal Medicina Department
Internal Medicine
N/A
Nephrology Department
Neurology
Oncology
Otorhinolaryngology Service
Pulmonology Unit
Rheumatology
Serviço de Cardiologia
Serviço de Cirugia
Serviço de Endocrinologia
Serviço de Hematologia
Serviço de Medicina Interna
Serviço de Ortopedia
Serviço de Otorrinolaringologia
Serviço de Pneumologia
Surgery Department
Unidade Local de Saúde Regional de Aveiro EPE

Clinical trials at this site (39)

Search interface

A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending

2024-514246-37-00 Idiopathic pulmonary fibrosis (IPF) 4
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Bronchiectasis 5 2025-08-21
Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting

2022-503012-16-00 Patients on treatment with Factor Xa Inhibitor needing 5 2022-07-20
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE… Recruiting

2025-521802-17-00 Erosive/inflammatory osteoarthritis of the hands 5 2026-01-30
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 IgA nephropathy 5 2025-11-12
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) 5 2024-10-21
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
A study to investigate efficacy, safety, and tolerability of mavorixafor in participants with congenital and acquired primary autoimmune and… Recruiting

2023-508482-32-00 Neutropenias 5 2024-07-22
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Recruiting

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo… Recruiting

2023-508963-58-00 Symptomatic hypertrophic cardiomyopathy (HCM) 4 2022-01-31
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended

2025-521918-26-00 HIV Infections 4 2026-02-11
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516814-39-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-20
A Proof of Concept study to assess the efficacy, safety and tolerability of itepekimab (antiIL33 mAb) in participants with chronic rhinosi… Ended

2024-515576-12-00 Respiratory tract diseases 4 2025-03-20
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Chronic Obstructive Pulmonary Disease 5 2024-05-15
A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended

2023-504993-40-00 Human immunodeficiency virus (HIV) 5 2024-02-14
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08